

Press Release/ASX Announcement

Melbourne, Australia, 22 February 2023.

Board changes adds Australian capital markets expertise to the Exopharm Board

- Dr Jennifer King resigns as a non-executive director with immediate effect.
- Mr Clarke Barlow joins the Board as a non-executive Director and brings Australian capital markets expertise to the Board.

Genetic medicine and exosome-based drug-delivery company Exopharm Limited (ASX: EX1) announces further progress and support from investors.

Changes within the Board

Dr Jennifer King, based in the USA, joined the Exopharm board on 31st August 2021 and has made significant contributions to the company since that time. Dr King has provided sound advice in relation to partnering, testing and product activities.

Dr King has decided to resign from her role as a non-executive director of the Company.

Chairman Mr Jason Watson said 'Jennifer has made a strong contribution to the Company's strategies and activities and brought her pharmaceutical industry perspective to Board discussions. We thank Jennifer for her contribution.'

Mr Clarke Barlow has consented to become a non-executive director of the company and will immediately fill the vacancy left by Dr King.

Clarke is an experienced non-executive director. Based in Perth, Clarke is a Financial Adviser and Capital Markets Specialist with over 20 years' experience in the Financial Services Industry in Australia and the United Kingdom.

Clarke has experience in structuring, operations and risk management of institutional structured products in the United Kingdom and has been a Derivatives Manager, responsible for establishing and managing derivatives trading desks for several Australian based stockbroking firms.

Clarke brings to Exopharm his extensive experience providing corporate advisory services for companies listed on the Australian Securities Exchange (ASX) across a variety of industries, with a particular focus on growth opportunities in the Biotechnology, Technology, Industrial and Resource industries, providing them with advice on business models & strategy, structuring of pre-IPO and IPO fund raisings, reverse takeovers, capital raisings, mergers and acquisitions, investor relations and general equity capital markets advice.

Clarke holds a Bachelor of Commerce degree from the University of Western Australia and is a Member of the Australian Institute of Company Directors (AICD).

Chairman Mr Jason Watson said 'Clarke will bring important Australian capital markets experience and insights to the Board, a capability-gap we have been seeking to fill for some time.'

By the Chairman – this release has been authorised by the Chairman.

[Company and Media Enquiries:](#)

Join our mailing list to receive updates:

<http://exo.ph/ExoMails>

www.exopharm.com

P: +61 (0)3 9111 0026

Ian Dixon
Managing Director

Tel: +61 418 561 907
ian.dixon@exopharm.com

[ABOUT EXOPHARM](#)

Exopharm (ASX:EX1) is a leader in advancing Genetic Medicines and other exosome-based medicines using exosomes or extracellular vesicles (EVs) as a chassis for improved and non-viral drug-delivery.

Exopharm (ASX:EX1) is pursuing a product pipeline-driven platform strategy. Exosomes can be loaded with a variety of active pharmaceutical ingredients (APIs) and can be targeted to selected cell-types and tissue types, improving the safety-profile of the APIs and providing better treatments. Exosomes can be used to deliver small molecule drugs, mRNA, DNA and other types of APIs.

Exosomes are an alternative means of drug-delivery inside the body, alongside technologies such as lipid nanoparticles (LNP), cell-penetrating peptides, viral vectors and liposomes.

Exopharm's exosome technologies solve important needs for the success of exosome medicines – **LEAP** manufacturing technology, **LOAD** API loading technologies and **EVPS** tropism technologies.

Exosome-based medicines could improve the treatment of many chronic or inherited medical conditions.

Exopharm is making its proprietary technologies available to pharmaceutical and biotechnology companies that want to harness exosome-delivery for their own products.

In addition, Exopharm is using its technology platform to enable its own product development programs - each aimed at delivering a transformative medicine for an unmet medical need.

FORWARD LOOKING STATEMENTS

This announcement contains forward-looking statements which incorporate an element of uncertainty or risk, such as 'intends', 'may', 'could', 'believes', 'estimates', 'targets', 'aims', 'plans' or 'expects'. These statements are based on an evaluation of current corporate estimates, economic and operating conditions, as well as assumptions regarding future events. These events are, as at the date of this announcement, expected to take place, but there cannot be any guarantee that such events will occur as anticipated or at all given that many of the events are outside of Exopharm's control or subject to the success of the Development Program. Furthermore, the Company is subject to several risks as disclosed in the Prospectus dated 6 November 2018.

For personal use only